News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2023 Caitlin E. Cox December 28, 2023
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Conference News AHA 2023 New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference? Shelley Wood November 13, 2023
News Daily News Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals Yael L. Maxwell October 19, 2023
News Daily News High-risk Plaques in Nonculprit Lesions Tied to Worse Post-MI Outcomes Caitlin E. Cox September 18, 2023
News Conference News ESC 2023 ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran Michael O'Riordan September 01, 2023
News Conference News ADA 2023 Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention Michael O'Riordan June 28, 2023
News Conference News EAS 2023 Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH Michael O'Riordan May 24, 2023
News Daily News Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly Yael L. Maxwell April 03, 2023
News Conference News ACC 2023 Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study Todd Neale March 10, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Daily News Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3 Michael O'Riordan January 16, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023